VYVGART: payments to doctors
Payments that named VYVGART as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $7.3M
- Providers
- 7,907
- Transactions
- 33,155
- Average per transaction
- $221
The per-transaction average — $221 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 7,907 providers the average total is $926, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Argenx US, Inc. | $7,320,667 | 100.0% |